• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

On top of ex­pir­ing Her­ceptin patents, Roche faces huge roy­al­ty loss­es in 2019

7 years ago
Pharma

As­cle­tis reaps record $400M from Hong Kong in­vestors in the ex­change's first-ever pre-rev­enue biotech list­ing

7 years ago
Financing
China

Now a three-time los­er, selume­tinib con­tin­ues to cause headaches as As­traZeneca dumps a failed PhI­II

7 years ago
R&D

FDA slaps a hold on Sarep­ta's Duchenne MD study in the wake of stel­lar ear­ly re­sults

7 years ago
R&D

Look­ing to mount an R&D turn­around, GSK gets slapped down at the FDA for a weak stab at COPD

7 years ago
Pharma

Ei­sai, Bio­gen bat­tered by con­tro­ver­sy over PhII Alzheimer's study af­ter post­ing pos­i­tive re­sults

7 years ago
R&D

Help want­ed: New CEO to run Gilead as John Mil­li­gan steps down

7 years ago
People

Acor­da shares tank as ap­peals court re­fus­es in­junc­tion against cheap Ampyra knock­offs

7 years ago
Pharma

Pfiz­er plans $465M man­u­fac­tur­ing fa­cil­i­ty at Michi­gan base; Chi­na's Ts­inghua Uni­ver­si­ty inks dis­cov­ery deal with ...

7 years ago
News Briefing

Take­da R&D team rings the block­buster bell with key PhI­II suc­cess in front­line lung can­cer

7 years ago
R&D

Mer­ck claims a need­ed win for Keytru­da with in­ter­im OS da­ta in head and neck can­cer

7 years ago
R&D

With a new HQ un­der con­struc­tion and Ab­b­Vie as a part­ner, Alec­tor grabs $133M round to fund a move in­to the clin­ic

7 years ago
Financing

Months af­ter IPO, No­var­tis spin­out resTOR­bio wins on PhI­Ib da­ta — stock soars

7 years ago
R&D

This is it? GSK rolls out a buzzy new R&D plan long on as­pi­ra­tions and short on per­for­mance goals

7 years ago
Bioregnum
R&D

Za­vante CEO sells his late-stage an­tibi­ot­ic biotech to Nabri­va — grab­bing the helm in the deal

7 years ago
People
Pharma

With moth­ers on erec­tile dys­func­tion drug, 11 new­born ba­bies die af­ter tri­al trig­gers lung prob­lems

7 years ago
R&D

Mer­ck hands Sutro $60M to start on im­munomod­u­la­to­ry drug dis­cov­ery; Eli Lil­ly spin­ning out an­i­mal health group

7 years ago
News Briefing

Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

7 years ago
Pharma

API man­u­fac­tur­er Cam­brex buys Ha­lo Phar­ma for $425M — ven­tur­ing in­to fin­ished dose man­u­fac­tur­ing

7 years ago
Deals

Fol­low­ing some clean sweeps in PhI­II, Ab­b­Vie gets an FDA OK on its top-10 block­buster prospect Orilis­sa

7 years ago
Pharma

As Ei­sai, Bio­gen plot a course to ac­cel­er­at­ed ap­provals for Alzheimer’s drug, a mob of skep­tics are wait­ing to ...

7 years ago
R&D
Pharma

Mar­ket slack­er Cel­gene does some­thing good for a change, look­ing to turn the cor­ner on past mishaps

7 years ago
R&D

Il­lu­mi­na's found­ing sci­en­tist launch­es soft­ware start­up to track fast-mu­tat­ing hos­pi­tal bugs

7 years ago
People
Startups

GSK banks on promis­ing da­ta from its PhI­II Gem­i­ni pro­gram to stare down Gilead on HIV — but there are plen­ty of ...

7 years ago
R&D
First page Previous page 1009101010111012101310141015 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.